Ken Lu
Direktor/Vorstandsmitglied bei GLOBAL CORD BLOOD CORPORATION
Aktive Positionen von Ken Lu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GLOBAL CORD BLOOD CORPORATION | Direktor/Vorstandsmitglied | 30.06.2009 | - |
| Independent Dir/Board Member | 30.06.2009 | - | |
| Fort Hill Capital Ltd. | Corporate Officer/Principal | - | - |
Karriereverlauf von Ken Lu
Ehemalige bekannte Positionen von Ken Lu
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| APAC Capital Advisors Ltd. | Gründer | 01.01.2004 | 01.01.2010 |
Credit Suisse First Boston (Hong Kong) Ltd.
 Credit Suisse First Boston (Hong Kong) Ltd. Financial ConglomeratesFinance Part of UBS Group AG, Credit Suisse First Boston (Hong Kong) Ltd. provides investment and financial services. The company is based in Hong Kong, Hong Kong. | Corporate Officer/Principal | 01.10.2001 | 01.05.2004 |
China Biologic Products, Inc.
 China Biologic Products, Inc. Pharmaceuticals: MajorHealth Technology China Biologic Products, Inc. operates as a biopharmaceutical company, which engages in the manufacture and distribution of plasma-based pharmaceutical products and other biological substances. Its products include human albumin, human immunoglobulin for intravenous injection, human Hepatitis B immunoglobulin, human rabies immunoglobulin, human immunoglobulin, human coagulation factor VIII, human prothrombin complex concentrate, and placenta polypeptide. The company was founded on December 20, 1989 and is headquartered in Beijing, China. | Direktor/Vorstandsmitglied | - | - |
Seres Asset Management Ltd.
 Seres Asset Management Ltd. Investment ManagersFinance Seres Asset Management Ltd. (Seres) is an independent hedge fund management firm headquartered in Hong Kong. The firm was founded as a joint venture in 2009 between Evan Erlanson, Ken Lu and Australian Unity Investments, the fund management arm of Australian Unity. Through the joint venture arrangement, Seres provides portfolio management of Asian equities in the form of hedge funds for institutional and retail clients. | Corporate Officer/Principal | - | - |
Ausbildung von Ken Lu
| Peking University | Undergraduate Degree |
| Brigham Young University | Graduate Degree |
| University of California, Los Angeles | Doctorate Degree |
Statistik
International
| Hong Kong | 5 |
| China | 3 |
| Vereinigte Staaten | 3 |
Operativ
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Independent Dir/Board Member | 1 |
Sektoral
| Consumer Services | 4 |
| Finance | 3 |
| Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GLOBAL CORD BLOOD CORPORATION | Health Services |
| Private Unternehmen | 5 |
|---|---|
| Fort Hill Capital Ltd. | |
Seres Asset Management Ltd.
Seres Asset Management Ltd. Investment ManagersFinance Seres Asset Management Ltd. (Seres) is an independent hedge fund management firm headquartered in Hong Kong. The firm was founded as a joint venture in 2009 between Evan Erlanson, Ken Lu and Australian Unity Investments, the fund management arm of Australian Unity. Through the joint venture arrangement, Seres provides portfolio management of Asian equities in the form of hedge funds for institutional and retail clients. | Finance |
| APAC Capital Advisors Ltd. | |
Credit Suisse First Boston (Hong Kong) Ltd.
Credit Suisse First Boston (Hong Kong) Ltd. Financial ConglomeratesFinance Part of UBS Group AG, Credit Suisse First Boston (Hong Kong) Ltd. provides investment and financial services. The company is based in Hong Kong, Hong Kong. | Finance |
China Biologic Products, Inc.
China Biologic Products, Inc. Pharmaceuticals: MajorHealth Technology China Biologic Products, Inc. operates as a biopharmaceutical company, which engages in the manufacture and distribution of plasma-based pharmaceutical products and other biological substances. Its products include human albumin, human immunoglobulin for intravenous injection, human Hepatitis B immunoglobulin, human rabies immunoglobulin, human immunoglobulin, human coagulation factor VIII, human prothrombin complex concentrate, and placenta polypeptide. The company was founded on December 20, 1989 and is headquartered in Beijing, China. | Health Technology |
